Background: Mycobacterium bovis BCG is a live, attenuated tuberculosis vaccine. While the vaccine protects infants from tuberculosis, complications including disseminated infections have been reported following vaccination. Genetically diverse BCG sub-strains now exist following continuous passaging of the original Pasteur strain for vaccine manufacture. This genetic diversity reportedly influences the severity of disseminated BCG infections and the efficacy of BCG immunization. Methods: M. bovis BCG was isolated from infants suspected of being infected with tuberculosis. The whole genome of the clinical isolates and BCG Moscow were sequenced using Illumina Miseq and the sequences were analysed using CLC Genomics Workbench 7.0, PhyResSE v1.0, and Parsnp. Results and conclusions: Genetic variations between the clinical strains and the reference BCG Copenhagen were identified. The clinical strains shared only one mutation in a secretion protein.
Introduction
Mycobacterium bovis bacillus Calmette-Guerin (BCG) is an attenuated live vaccine conferring protection against disseminated forms of tuberculosis (TB) in infants. Besides various complications following vaccination with the BCG vaccine (Movahedi et al., 2011; Ying et al., 2014) , the protective efficacy of the vaccine against pulmonary TB is inconsistent, ranging from 0 to 80% (Copina et al., 2014; Pan et al., 2011) . The inconsistency in protective efficacy may be associated with the host's immune state, routes of vaccine administration, and possible genetic heterogeneity of circulating BCG strains, resulting from continuous passaging of the original BCG Pasteur strain (Dockrell and Smith, 2017) .
The BCG vaccine is derived from virulent M. bovis through serial passaging on potato bile media. The BCG vaccine shares biological and genetic properties with virulent Mycobacterium tuberculosis and M. bovis, creating a risk of reversion to the invasive phenotype (Jia et al., 2017) . Pathogenic M. bovis and M. tuberculosis share genes that are absent in BCG strains (Mahairas et al., 1996; Nieuwenhuizen and Kaufmann, 2018) . Additionally, different BCG sub-strains may either have or lack the region of difference two (RD2), and only BCG Pasteur has the tandem duplication 1, DU1 (Li et al., 2015) . These studies show that BCG strains are different from pathogenic Mycobacterium species and that different BCG strains are phylogenetically related.
M. tuberculosis complex (MTBC) is routinely identified using the MPT64 antigen test and the line probe assay GenoType MTBDRplus in our setting, at the National Health Laboratory Services, Tshwane Academic Division (NHLS/TAD). The GenoType MTBDRplus assay simultaneously identifies MTBC, as well as rifampicin (RIF) and isoniazid (INH) resistance, but does not identify MTBC to the species level.
MTBC includes the following Mycobacterium species: M. tuberculosis, M. bovis ssp. bovis, M. bovis ssp. caprae, Mycobacterium africanum, Mycobacterium microti, Mycobacterium canetti, and the vaccine strain, M. bovis BCG. The different species can be identified using the GenoType MTBC line probe assay (Neonakis et al., 2007) . This line probe assay identifies and differentiates MTBC species based on gyrB polymorphisms and the RD1 deletion; the test strips used are coated with specific oligonucleotides targeting gyrB polymorphisms and the RD1 deletion (Richter et al., 2003) . However, this test is expensive and BCG infections are only diagnosed upon request. In most cases, BCG infections would be missed and reported as TB.
In this study, two clinical BCG vaccine strains were isolated from infants suspected of being infected with TB and BCGiosis, respectively. The isolates were previously confirmed as BCG strains using the Hain MTBC line probe assay (Hain Lifescience, Nehren, Germany) as part of the routine diagnosis at the NHLS/TAD; the results were obtained from the laboratory information system (LIS). The invasiveness of the isolates was suspected to have been caused by mutations in the clinical isolates. This study therefore aimed to identify genetic variations within the clinical isolates and to analyse the phylogenetic relationship between the clinical isolates and other M. bovis species. To our knowledge, this is the first study in South Africa and Africa to compare clinical M. bovis BCG genomes with reference M. bovis BCG genomes.
Methods

Study design and sample description
This was a retrospective, descriptive study of two clinical M. bovis BCG isolates. The study was approved by the Research Ethics Committee, University of Pretoria (reference number 59/2017).
The two clinical isolates (designated M1_S48 and M2_S49) were previously characterized as susceptible to RIF and INH, using the GenoType MTBDRplus assay (Hain Lifescience, Nehren, Germany). The lyophilized BCG Moscow (designated BCG_S50; Serum Institute of India, India) was used as a live BCG reference. The live BCG Danish (Copenhagen) strain was not available due to a shortage and change of the BCG vaccine strain used in South Africa; hence the BCG Danish genome stored at GenBank was used as a reference.
Phenotypic methods
The two clinical isolates (M1_S48 and M2_S49) and the M. bovis BCG Moscow strain (Serum Institute of India, India) were sub-cultured in Lowenstein-Jensen (LJ) (NICD, South Africa) and the Middlebrook 7H9 MGIT (Mycobacterial Growth Indicator Tube) media (Becton, Dickson and Company, Sparks, MD, USA). Isolates that grew on the Middlebrook 7H9 MGIT medium and flagged positive on the Bactec MGIT 960 instrument within 5 days were tested for pyrazinamide (PZA) drug susceptibility using the BD Bactec MGIT 960 system (Becton, Dickson and Company, Sparks, MD, USA). The manufacturers' instructions were followed for all of the tests.
Genomic DNA extraction and sequencing
Genomic DNA (gDNA) was extracted using the Zymo Research Bacterial/Fungal DNA extraction kit (The Epigenetic Company, USA) according to the manufacturer's instructions. The gDNA was extracted from isolates grown on LJ medium and the gDNA libraries were prepared using the Nextera DNA Sample Prep Kit (Illumina Inc., San Diego, CA, USA). Paired-end whole-genome sequencing was done using the Illumina Miseq sequencing platform (Illumina Inc., San Diego, CA, USA) with 100Â coverage.
Genomic analysis
The sequence data were analysed using CLC Genomics Workbench 7.0, Mauve 2.4.0 (http://darlinglab.org/mauve/download.html), and the PhyResS v1.0 server (www.phyresse.org/). The genomes of different Mycobacterium strains were downloaded from GenBank and PATRIC (https://www.patricbrc.org/) for genomic comparison and phylogenetic analysis.
The genomes of the M1_S48, M2_S49, and BCG_S50 isolates were aligned against BCG Copenhagen using CLC Genomics Workbench 7.0 (Qiagen) and against the M. tuberculosis H37Rv reference strain using progressive Mauve, as described by Darling et al. (2004) . A probabilistic variant detection algorithm was used to identify genetic variations between genomes. The following parameters were set: the read filter was set to ignore non-specific variation and broken read pairs. The significance threshold was set to a minimum coverage of 10 and variant probability of 95.0, to require the presence of both forward and reverse sequences, ignore variants in non-specific region(s), and require a variant count of 2; the maximum expected variant was set to 2. PhyResSE was used to search for antibiotic resistance mutations, and Parsnp was used to analyse phylogenetic relatedness between the clinical BCG genomes (M1_S48 and M2_S49) and the downloaded reference genomes. The Parsnp command line with the "-C 1000 -c" flag was run to force alignment over collinear regions. The trees generated were viewed with Gingr The growth control tubes only contained the isolates being tested. Each drug was added into a separate tube with the tested isolate and incubated along with the growth control. The BD Bactec MGIT 960 instrument monitors and compares growth of the isolates in the drug-containing tubes with the isolates in the growth control tubes and automatically interprets the results. Results and discussion M. bovis and its derivative M. bovis BCG vaccine are intrinsically resistant to PZA (Ritz et al., 2009) . As expected, the M1_S48, M2_49, and BCG Moscow in this study were also resistant to PZA (Table 1) .
The draft genome sequences of the two isolates, M1_S48 and M2_S49, were 2 767 203 bp and 1 432 828 bp, respectively. These genome sizes are significantly smaller than the previously sequenced BCG genomes (Borgers et al., 2019) ; the reasons for this are not known, although it may suggest that some genes are missing in these isolates, making their genomes smaller. Annotation with the NCBI Prokaryotic Genome Annotation Pipeline identified 3999 coding genes, 3999 coding CDS, 51 RNA (3 rRNA, 45 tRNA, 3 ncRNA), 187 pseudogenes, and three CRISPR arrays in the genome of M1_48. In the genome of M2_49, 4027 coding genes, 51 RNA genes (3 rRNA, 45 tRNA, 3 ncRNA), 205 pseudogenes, and two CRISPR arrays were identified.
Genomic analysis using CLC Genomics Workbench 7.0 identified variations in several protein coding genes in the clinical isolates and the reference BCG Copenhagen genome. The M1_S48 genome had mutations in 23 non-coding sequences and 48 coding sequences including hypothetical proteins (23.9%), proline glutamate polymorphic GC-rich repetitive sequences (PE-PGRs, 11.3%), membrane anchored mycosin (11.4%), and several other functional genes ( Table 2 ). The M2_S49 genome had two mutations (Table 3) . Both isolates shared a mutation causing K → G amino acid substitution in the secretion protein, believed to be the ESX-5 protein (CLC Genomics Workbench 7.0). M. tuberculosis complex consists of five type IIV or ESX (ESX-1 to ESX-5) secretion systems. ESX-1, ESX-3, and ESX-5 are associated with protein secretion and it was suspected that one of them could be the secretion protein identified with mutation in this study (Ates et al., 2015) . ESX-1 is encoded by the RD1 region and this region is deleted in all M. bovis BCG sub-strains and was therefore ruled out. ESX-3 plays a role in the acquisition of metal ions and survival of M. tuberculosis (Knudsen et al., 2014) . There are, however, no data on ESX-3 associated with M. bovis BCG. On the other hand, ESX-5 plays a role in outer membrane permeability and has been shown to play an essential role in M. bovis BCG growth (Ates et al., 2015) .
As expected, when compared to BCG Copenhagen, the BCG Moscow genome had more genetic variability (Supplementary material, Table S1 ). Different BCG sub-strains are genetically diverse, and it has been shown that BCG Moscow (also known as BCG Russia) is distantly related to BCG Copenhagen (Abdallah et al., 2015; Copina et al., 2014) . This explains the genetic variability observed between these two strains.
The membrane-anchored mycosin genes encode a family of subtilisin-like proteases, designated MycP1-MycP5 (Brown et al., 2000; Fang et al., 2016) . These genes comprise a part of the ESX system that is involved in the virulence of MTBC and they are also present in BCG strains. Only the mycosins MycP2, MycP3, and MycP5 have previously been identified in BCG strains and they are believed to be essential for the growth of the bacteria. Additionally, MycP5 reportedly facilitates the secretion of the PE/PPE (prolineglutamate/proline-proline-glutamate) proteins. Mutations in these genes may therefore interfere with mycobacterial growth and secretions of the PE/PPE proteins (Chen, 2016; Fang et al., 2016) . The PE-PGRs are a subfamily of the PE proteins. These proteins contain conserved sequences at the N-terminus and polymorphic repeat units at the C-terminus. Reports suggest that the PE-PGR proteins elicit an immune response and are essential for mycobacterial pathogenesis (Tiwari et al., 2012) . The role of the PE-PGRs in BCG virulence is not well known.
The RD1 region was found to be missing in M1_S48, M2_S49, and BCG_S50, when aligned against M. tuberculosis H37Rv (Figure 1) . This result therefore confirms the clinical isolates to be M. bovis BCG.
Analysis with PhyResSE identified various resistance mutations in the clinical isolates, with both isolates having PZA resistance mutations in the pncA gene. The BCG M2_S49 isolate had PZA resistance mutations in pncA: His57Asp (cac/gac). Previous studies have also reported a His57Asp (cac/gac) mutation in M. bovis and M. bovis BCG, which is associated with intrinsic PZA resistance (Feuerriegel et al., 2014; Jureen et al., 2008) . BCG M1_S48 had the following antibiotic resistance-conferring mutations: Ser450Leu (tcg/ttg) in rpoB (RIF resistance); Ile194Thr (atc/acc) in inhA and Arg268His (cgc/cac) in ndh (INH and ethionamide resistance); Gly97Asp (ggt/gat) in pncA (PZA resistance); and Met306Val (atg/ gtg) in embB (ethambutol resistance). This suggests that the strain could be multidrug-resistant.
For M1_S48, the MTBDRplus assay and genomic analysis showed discordant drug susceptibility results. As mentioned above, both isolates were susceptible to INH and RIF according to the GenoType MTBDRplus assay, despite identifying mutations in the rpoB and inhA genes, which confer resistance to RIF and INH, respectively. Routine drug susceptibility testing at the NHLS, Pretoria is done using the GenoType MTBDRplus line probe assay. The assay uses strips that are coated with probes specific for some regions of the inhA and rpoB genes, and mutations occurring outside of the included regions cannot be detected. Failing to detect these mutations would result in false-negative results and negatively impact patients, as incorrect drug regimens would be prescribed. Incorrect drug regimens have also been associated with the spread of drug-resistant TB strains (Lange et al., 2018) . To improve the prescription of correct drug regimens, the results of the MTBDRplus assay should be validated with the phenotypic drug-susceptibility testing (DST) method, and more resistancemediating regions should be added to test strips to improve the diagnosis of drug-resistant strains. Moreover, whole genomebased diagnostics for TB should be adopted in the long-term in South Africa, as has been done recently in the UK (Cabibbe et al., 2018) , to improve the efficient diagnosis of MTBC and drug resistance.
Confirmatory phenotypic drug susceptibility testing for RIF, INH, and ethambutol could not be performed to confirm the resistance genotype in this study. The isolates failed to grow when sub-cultured from storage (at À70 C). This is therefore a limitation of the study.
The phylogenetic analysis showed that M1_S48 was more closely related to the BCG Moscow strain (Serum Institute of India, India); these strains clustered together on the phylogenetic tree ( Figure 2) . These two strains also branched from the same ancestor as the East African Indian strain (M. tuberculosis EAI5/NITR2060), (Abdallah et al., 2015; Bottai and Brosch, 2016) . This suggests that M2_S49 is closely related to the BCG Danish strain. As expected M. bovis isolated from different animals in different countries branched out from the same root in different clades. Few cases of BCGiosis have been documented, making it difficult to build an adequate sample size. Similarly, most cases of BCGiosis are not reported, making it difficult to follow up on the clinical outcomes associated with genetic variations of BCG strains. The mutated genes identified in this study have not been reported previously as virulence factors, and this study did not include immunological assays to identify the impact of the mutation on the patient. In addition, it was not possible to follow up on the clinical outcomes of the infected patients, limiting the clinical application of this study. It is also worrying that two genetically diverse BCG strains are circulating in South Africa simultaneously, because adverse events cannot be attributed to a specific strain. This study thus presents valuable unprecedented information on the genomic characteristics of BCGiosis in South Africa and lays a foundation for further exploration in this field.
In conclusion, the clinical BCG isolates were genetically distinct when compared to BCG Copenhagen. Various mutations were identified in coding sequences in the form of deletions, insertions, and single nucleotide variations. Both isolates shared a mutation causing a substitution of glycine to lysine amino acid in the ESX-5 secretion protein. Isolate, M1_S49 contained multiple mutations in antibiotic resistance genes, which would potentially complicate treatment.
The two isolates were phylogenetically distinct, clustering far apart when compared to global BCG isolates. The study results imply that two different BCG strains may be circulating in South Africa, but as BCGiosis is under-reported, it is difficult to associate the BCG vaccine strain administered and the BCG strain supplied with specific adverse events. Whole-genome sequencing was used successfully to identify two of the BCG vaccine strains circulating in South Africa and this tool is recommended in routine diagnosis to improve MTBC and resistance detection. The data gleaned from this study could be useful for molecular tracking of the distribution of these BGC strains in South Africa.
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